Furtheranalysis enrolling other molecular entities (e.g., tumor-associatedmRNAs, miRNAs, proteins), relevant tumor-derived mutations (e.g.,EGFRviii; copy number variations in PTEN and CDKN2A/B genes) and different EV isolations methodologies,is encouraged to reach clinical translation. The gene discussed is CDKN2A; the disease is neoplasm.